Your browser doesn't support javascript.
loading
MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F; Winham, Stacey J; Wagner, Philipp; Traficante, Nadia; Toloczko, Aleksandra; Tiezzi, Daniel G; Taran, Florin Andrei; Sinn, Peter; Sieh, Weiva; Sharma, Raghwa; Rothstein, Joseph H; Ramón Y Cajal, Teresa; Paz-Ares, Luis; Oszurek, Oleg; Orsulic, Sandra; Ness, Roberta B; Nelson, Gregg; Modugno, Francesmary; Menkiszak, Janusz; McGuire, Valerie; McCauley, Bryan M; Mack, Marie; Lubinski, Jan; Longacre, Teri A; Li, Zheng; Lester, Jenny; Kennedy, Catherine J; Kalli, Kimberly R; Jung, Audrey Y; Johnatty, Sharon E; Jimenez-Linan, Mercedes; Jensen, Allan; Intermaggio, Maria P; Hung, Jillian; Herpel, Esther; Hernandez, Brenda Y; Hartkopf, Andreas D; Harnett, Paul R; Ghatage, Prafull; García-Bueno, José M; Gao, Bo; Fereday, Sian; Eilber, Ursula; Edwards, Robert P; de Sousa, Christiani B; de Andrade, Jurandyr M; Chudecka-Glaz, Anita; Chenevix-Trench, Georgia.
Afiliación
  • Block MS; Department of Medical Oncology, Mayo Clinic, Rochester, MN.
  • Vierkant RA; Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
  • Rambau PF; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Pathology Department, Catholic University of Health and Allied Sciences-Bugando, Mwanza, Tanzania.
  • Winham SJ; Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
  • Wagner P; Tübingen University Hospital, Department of Women's Health, Tübingen, Germany.
  • Traficante N; Sir Peter MacCallum Department of Oncology, the University of Melbourne, Parkville, Victoria, Australia.
  • Toloczko A; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Tiezzi DG; Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Taran FA; Tübingen University Hospital, Department of Women's Health, Tübingen, Germany.
  • Sinn P; Department of Pathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Sieh W; Department of Population Health Science and Policy, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Sharma R; Pathology West ICPMR Westmead, Westmead Hospital, the University of Sydney, Sydney, Australia; University of Western Sydney at Westmead Hospital, Westmead, New South Wales, Australia.
  • Rothstein JH; Department of Population Health Science and Policy, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Ramón Y Cajal T; Medical Oncology Service, Hospital Sant Pau, Barcelona, Spain.
  • Paz-Ares L; H12O-CNIO Lung Cancer Clinical Research Unit, Madrid, Spain; Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Oszurek O; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Orsulic S; Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Ness RB; University of Texas School of Public Health, Houston.
  • Nelson G; Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Modugno F; Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA; Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA; Womens Cancer Research Program, Magee-Womens Research Institute and Univ
  • Menkiszak J; Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.
  • McGuire V; Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA.
  • McCauley BM; Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
  • Mack M; Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
  • Lubinski J; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Longacre TA; Department of Pathology, Stanford University, Stanford, CA.
  • Li Z; Department of Health Sciences Research, Mayo Clinic, Rochester, MN; Department of Gynecologic Oncology, the Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital), Kunming, China.
  • Lester J; Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Kennedy CJ; Centre for Cancer Research, the Westmead Institute for Medical Research, the University of Sydney, Sydney, New South Wales, Australia; Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Kalli KR; Department of Medical Oncology, Mayo Clinic, Rochester, MN.
  • Jung AY; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Johnatty SE; Department of Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Jimenez-Linan M; Department of Histopathology, Addenbrookes Hospital, Cambridge, UK.
  • Jensen A; Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Intermaggio MP; School of Women's and Children's Health, University of New South Wales, Sydney, Australia.
  • Hung J; Centre for Cancer Research, the Westmead Institute for Medical Research, the University of Sydney, Sydney, New South Wales, Australia; Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Herpel E; Tissue Bank of the National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany; Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
  • Hernandez BY; Cancer Center, University of Hawaii, Honolulu, HI.
  • Hartkopf AD; Tübingen University Hospital, Department of Women's Health, Tübingen, Germany.
  • Harnett PR; Centre for Cancer Research, the Westmead Institute for Medical Research, the University of Sydney, Sydney, New South Wales, Australia; Crown Princess Mary Cancer Centre, Westmead Hospital, the University of Sydney, Sydney, Australia.
  • Ghatage P; Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • García-Bueno JM; Oncology Department, Hospital General de Albacete, Madrid, Spain.
  • Gao B; Centre for Cancer Research, the Westmead Institute for Medical Research, the University of Sydney, Sydney, New South Wales, Australia; Crown Princess Mary Cancer Centre, Westmead Hospital, the University of Sydney, Sydney, Australia.
  • Fereday S; Department of Cancer Genomics and Genetics, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
  • Eilber U; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Edwards RP; Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA.
  • de Sousa CB; Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • de Andrade JM; Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
  • Chudecka-Glaz A; Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.
  • Chenevix-Trench G; Department of Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Mayo Clin Proc ; 93(3): 307-320, 2018 03.
Article en En | MEDLINE | ID: mdl-29502561
OBJECTIVE: To evaluate myeloid differentiation primary response gene 88 (MyD88) and Toll-like receptor 4 (TLR4) expression in relation to clinical features of epithelial ovarian cancer, histologic subtypes, and overall survival. PATIENTS AND METHODS: We conducted centralized immunohistochemical staining, semi-quantitative scoring, and survival analysis in 5263 patients participating in the Ovarian Tumor Tissue Analysis consortium. Patients were diagnosed between January 1, 1978, and December 31, 2014, including 2865 high-grade serous ovarian carcinomas (HGSOCs), with more than 12,000 person-years of follow-up time. Tissue microarrays were stained for MyD88 and TLR4, and staining intensity was classified using a 2-tiered system for each marker (weak vs strong). RESULTS: Expression of MyD88 and TLR4 was similar in all histotypes except clear cell ovarian cancer, which showed reduced expression compared with other histotypes (P<.001 for both). In HGSOC, strong MyD88 expression was modestly associated with shortened overall survival (hazard ratio [HR], 1.13; 95% CI, 1.01-1.26; P=.04) but was also associated with advanced stage (P<.001). The expression of TLR4 was not associated with survival. In low-grade serous ovarian cancer (LGSOC), strong expression of both MyD88 and TLR4 was associated with favorable survival (HR [95% CI], 0.49 [0.29-0.84] and 0.44 [0.21-0.89], respectively; P=.009 and P=.02, respectively). CONCLUSION: Results are consistent with an association between strong MyD88 staining and advanced stage and poorer survival in HGSOC and demonstrate correlation between strong MyD88 and TLR4 staining and improved survival in LGSOC, highlighting the biological differences between the 2 serous histotypes.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Receptor Toll-Like 4 / Factor 88 de Diferenciación Mieloide / Carcinoma Epitelial de Ovario Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Mayo Clin Proc Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Receptor Toll-Like 4 / Factor 88 de Diferenciación Mieloide / Carcinoma Epitelial de Ovario Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Mayo Clin Proc Año: 2018 Tipo del documento: Article